SCHEMBL11486385

SCHEMBL11486385

Nc1ccc(N2CCOC2=O)c(Cl)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
GAA P10253 2/20 0.57
ALDH1A1 P00352 5/20 0.51
POLB P06746 2/20 0.51
KDM4E B2RXH2 1/20 0.47
RAD52 P43351 1/20 0.47
CYP3A4 P08684 4/20 0.46
HTT P42858 1/20 0.46
NFKB1 P19838 1/20 0.46
PMP22 Q01453 1/20 0.46
TDP1 Q9NUW8 1/20 0.40
TSHR P16473 2/20 0.38
CMA1 P23946 3/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
ALDH3A1 P30838 1/20 0.36
ALDH1A3 P47895 1/20 0.36
P2RX7 Q99572 1/20 0.35
CA1 P00915 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4515367 0.91 MAPT (0.54) MAPTSMN1; SMN2GAAALDH1A1POLB
SCHEMBL29182832 0.83 MAPT (0.39) MAPTSMN1; SMN2GAACMA1ALDH3A1
SCHEMBL5388815 0.81 MAPT (0.50) MAPTSMN1; SMN2GAAALDH1A1KDM4E
SCHEMBL5652989 0.81 MAPT (0.45) MAPTSMN1; SMN2GAAALDH1A1POLB
SCHEMBL76858 0.78 MAPT (0.62) MAPTSMN1; SMN2GAAALDH1A1POLB
SCHEMBL19308380 0.78 ATAD2 (0.39) MAPTSMN1; SMN2GAAALDH1A1KDM4E
SCHEMBL16703518 0.78 MAPT (0.38) MAPTSMN1; SMN2GAAALDH1A1POLB
SCHEMBL11491917 0.78 ALDH1A1 (0.50) MAPTSMN1; SMN2GAAALDH1A1HTT
SCHEMBL23466566 0.77 KMT2A (0.53) MAPTSMN1; SMN2ALDH1A1POLBKDM4E
SCHEMBL29758149 0.77 KMT2A (0.53) MAPTSMN1; SMN2ALDH1A1POLBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9751843-B2 Substituted uracils and use thereof BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-09-05 US disclosed
US-20160297771-A1 SUBSTITUTED URACILS AND USE THEREOF BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-10-13 US disclosed
EP-3066098-A1 SUBSTITUTED URACILS AND USE THEREOF Bayer Pharma Aktiengesellschaft (DE) 2016-09-14 EP disclosed
WO-2015067630-A1 SUBSTITUTED URACILS AND USE THEREOF BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-05-14 WO disclosed
US-4226612-A Certain herbicidal (2-oxo-3-oxazolidinyl)phenylureas SHELL OIL COMPANY (US) 1980-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160297771-A1 SUBSTITUTED URACILS AND USE THEREOF UNG, UMPS, TYMP MAPT 3023/4885SMN1; SMN2 1084/4885GAA 293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.